NEWS & MEDIA · February 5, 2025
BioPharma APAC: R-biolin matches Novolin R in pre-clinical tests, gears up for 50× scale-up and human trials
This article summarizes coverage published on February 5, 2025.
About this coverage
BioPharma APAC covered preclinical results for rBIO’s insulin candidate, R-biolin. The report described performance comparable to Novolin R in animal studies and plans to move toward larger-scale manufacturing and human trials.
The coverage highlights the connection between scientific validation and manufacturing scale. At the time of publication, rBIO was planning a fifty-fold increase in production scale as a next step in development.
This is an archived news summary; development plans described here reflect the original publication date.